This web site uses cookies. Do you accept the use of external cookies? Yes No Know more x
Survey about achondroplasia
We have designed a questionnaire with the purpose to better know the population connected to achondroplasia.
The questionnaire is optional and anonymous. The data obtained will be used for statistical purposes and to better understand the natural history of achondroplasia. Please consider answering.
If you would like to take the survey later, you can click on the link at the top "Register at BA"
Go to the survey Not now No, thanks

To better understand CRISPR-Cas9


CRISPR Therapeutics is now evaluating therapies for both in vivo and ex-vivo treatments [1].

In vivo treatments are made by administering CRISPR-CAS9 directly into the human body using a vector (of viral origin, nanoparticles, etc.) to carry the necessary components into target cells.

Ex vivo treatments require the removal of specific cells from the body, editing the gene that's causing the patient's disease and delivering the modified cells back into the patient [2].

our programs therapeutic approach
Image from: CRISPR Therapeutics


Many researchers are currently testing the limits and possibilities of CRISPR-Cas9 using both these techniques [3].

CRISPR-Cas9 is a major discovery in science and can change the future of medicine and pharmaceutics industry.

Sources


  1. CRISPR THERAPEUTICS. (2015). No Title. Available from: http://crisprtx.com/our-programs/our-pipeline.php
  2. Savić, N., & Schwank, G. (2015). Advances in therapeutic CRISP_Cas9 genome editing. Translational Research, 168, 15–21. Available from: https://doi.org/10.1016/j.trsl.2015.09.008
  3. Dai, W.-J., Zhu, L.-Y., Yan, Z.-Y., Xu, Y., Wang, Q.-L., & Lu, X.-J. (2017). CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles. Molecular Therapy - Nucleic Acids, 5. Available from: https://doi.org/10.1038/mtna.2016.58 
To view this site you need Internet Explorer 8 (or a higher version)
or another internet browser.

Thank You.